Regulatory Approvals, Product Launches, and Steady Sales Show Signs of Growth - Research Report on Johnson & Johnson, Bristol

Regulatory Approvals, Product Launches, and Steady Sales Show Signs of Growth
- Research Report on Johnson & Johnson, Bristol-Myers Squibb, Actavis, Edwards
                         Lifesciences, and Health Net

PR Newswire

NEW YORK, July 30, 2013

NEW YORK, July 30, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Johnson &
Johnson (NYSE: JNJ), Bristol-Myers Squibb Company (NYSE: BMY), Actavis Inc.
(NYSE: ACT), Edwards Lifesciences Corp. (NYSE: EW), and Health Net, Inc.
(NYSE: HNT). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Johnson & Johnson Research Report

On July 18, 2013, Janssen Biotech, Inc., a Johnson & Johnson (Johnson &
Johnson) company, announced that the US Food and Drug Administration (FDA) has
approved SIMPONI ARIA (golimumab) for infusion for the treatment of adults
with moderately to severely active rheumatoid arthritis (RA) in combination
with methotrexate. According to Janssen, SIMPONI ARIA, the only fully-human
anti-tumor necrosis factor (TNF)-alpha infusible therapy, has been shown to
significantly improve signs and symptoms of physical function, and inhibit the
progression of structural damage. Sergio Schwartzman, M.D., Director,
Inflammatory Arthritis Center, Hospital for Special Surgery, Associate
Professor, Weill Cornell Medical College, and Advisory Board Member, said,
"The approval of SIMPONI ARIA offers rheumatologists a new anti-TNF infusible
treatment for patients who demonstrate an inadequate response to methotrexate;
having treatment options remains critical for us to continue to meet the needs
of our patients." The Full Research Report on Johnson & Johnson - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/07a8_JNJ]

--

Bristol-Myers Squibb Company Research Report

On July 25, 2013, Bristol-Myers Squibb Company (Bristol-Myers Squibb) reported
its financial results for Q2 2013. Net sales decreased 8.9% YoY to $4.0
billion. Net earnings attributable to Bristol-Myers Squibb were $536 million
or $0.32 per diluted share in Q2 2013 compared to $645 or $0.38 per diluted
share in Q2 2012. Lamberto Andreotti, Chief Executive Officer of Bristol-Myers
Squibb, said, "In the second quarter, the strength in the performance of some
of our key products, the important data we presented across our portfolio and
the key regulatory filings we made in the U.S. strengthen our confidence as we
build a solid foundation for future growth." The Full Research Report on
Bristol-Myers Squibb Company - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/81a9_BMY]

--

Actavis Inc. Research Report

On July 25, 2013, Actavis Inc. (Actavis) reported its financial results for Q2
2013. Net revenue increased 46.8% YoY to approximately $2 billion. On a GAAP
basis, the Company reported net loss of $564.6 million or $4.27 per diluted
share in Q2 2013 compared to net loss of $62.2 million or $0.49 per diluted
share in Q2 2012. GAAP results included an impairment charge pertaining to a
routine annual impairment testing. Paul Bisaro, President and Chief Executive
Officer of Actavis, said, "Actavis delivered another exceptional quarter of
double-digit sales and earnings growth powered by strong generics launches in
global markets by Actavis Pharma, continued strong sales of core specialty
Brand products and consistent execution by our Global Operations team." The
Full Research Report on Actavis Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/4997_ACT]

--

Edwards Lifesciences Corp. Research Report

On July 25, 2013, Edwards Lifesciences Corp. (Edwards Lifesciences) reported
its financial results for Q2 2013. Net sales increased 7.3% YoY to $517.2
million. Net income was $94.1 million or $0.82 per diluted share, compared to
net income of $67.8 million or $0.57 per diluted share in Q2 2012. Michael A.
Mussallem, Chairman and Chief Executive Officer of Edwards Lifesciences, said,
"We are pleased to report solid second quarter results, driven by strong sales
of transcatheter and surgical heart valves in both the U.S. and Europe. Our
SAPIEN launch in the U.S. continues to be highlighted by very high procedural
success rates and we are gratified to see this therapy changing the lives of
so many patients." The Full Research Report on Edwards Lifesciences Corp. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/48b8_EW]

--

Health Net, Inc. Research Report

On July 25, 2013, Health Net Inc. (Health Net) reported its financial results
for Q2 2013. Total revenues decreased 3.6% YoY to $2.7 billion. Net income was
$33.5 million or $0.42 per diluted share in Q2 2013 compared to net income of
$124.6 million or $1.48 per diluted share in Q2 2012. Q2 2013 GAAP results
include approximately $12.9 million in Corporate/Other pretax expenses,
primarily severance costs resulting from the Company's continuing efforts to
address scale issues. Q2 2012 results also include a $119.4 million net gain
or $1.42 per diluted share from the sale of the Company's Medicare PDP
business. The Full Research Report on Health Net, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/6995_HNT]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

http://AnalystsCorner.com



SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)